Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Heterogeneity of treatment effect

15 evidence topics · 23 sources

Comorbidity-guided selection: inflammatory bowel disease, diabetes, cancer history, and latent tuberculosis

“In patients with psoriasis and IBD, we recommend preferentially using approved targeted therapies with documented efficacy in these conditions:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We suggest against the use of IL17 inhibitors in patients with inflammatory bowel disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“If alternative treatments are available, we suggest prescribing alternatives to MTX in patients with type 2 diabetes (with concomitant metabolic syndrome and/or signs of liver damage).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For patients in remission of cancer for more than 5 years, we recommend selecting the most appropriate option for psoriasis treatment independent of the cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For patients with latent TB infection, we recommend choosing one of the following options:” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“acitretin, apremilast, ciclosporin, dimethyl fumarate, MTX, or phototherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“We suggest against the use of deucravacitinib” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“in patients with latent TB infections unless there are no other suitable treatment options.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Due to lack of data concerning the reactivation risk” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Prior biologic or apremilast exposure: deucravacitinib real-world response through 52 and 104 weeks